{
    "clinical_study": {
        "@rank": "75", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate Racivir. The safety, most effective dosage, and how\n      the body reacts to Racivir will be studied."
        }, 
        "brief_title": "A 14-Day Study of Racivir When Used in Combination in HIV-Infected Males", 
        "completion_date": "December 2002", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a 14-day study with a 21-day follow-up period. During the 14-days of active\n      study period, participants will receive Racivir once daily in combination with efavirenz and\n      stavudine. Following the administration of the first and last dose of study medication,\n      patients will remain in the clinic overnight. During the study there will be medical and\n      medication histories taken, physical examinations, vital sign measurements, EKGs, and\n      routine clinical laboratory tests."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Subjects may be eligible to participate if they:\n\n          -  Are males with HIV infection with a positive HIV antibody test\n\n          -  Have an HIV-RNA copy number of \u2265 5000 copies/ml (Roche assay)\n\n          -  Have CD4+ cell counts \u2265 50 cells/ml\n\n          -  Are 18-45 years of age, inclusive\n\n          -  Have a body mass index (BMI) \u2265 18 kg/m2\n\n          -  Are antiretroviral nucleoside reverse transcriptase inhibitor-naive\n\n          -  Have read and understand the informed consent,and is able and willing to comply with\n             study procedures\n\n        Exclusion Criteria\n\n        Subjects may not participate if they:\n\n          -  Have clinically significant ECG abnormalities\n\n          -  Have clinically significant abnormalities in any safety laboratory parameters\n\n          -  Have an ALT value \u2265 3xUNL\n\n          -  Have previously participated in this trial\n\n          -  Have participated in another trial of an investigational drug within the last 3\n             months or are currently participating in another trial of an investigational drug\n\n          -  Have a history of chronic alcohol or drug abuse within the last 6 months\n\n          -  Have a positive urine drug screening\n\n          -  Have a positive alcohol breath test\n\n          -  Have any medical or psychiatric condition, which in the opinion of the investigator\n             would jeopardize or compromise the subject\u2019s ability to participate in this trial\n\n          -  Have a known hypersensitivity to any components of the trial medication or\n             comparative drugs as stated in this protocol"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "18", 
        "firstreceived_date": "June 24, 2002", 
        "id_info": {
            "nct_id": "NCT00040300", 
            "org_study_id": "CI-PSI-004-02-101"
        }, 
        "intervention": {
            "intervention_name": "Racivir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "2',3'-dideoxy-5-fluoro-3'-thiacytidine"
        }, 
        "keyword": [
            "treatment experienced", 
            "HIV", 
            "Phase I", 
            "Combination Therapy"
        ], 
        "lastchanged_date": "July 18, 2005", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "removed_countries": {
            "country": "Germany"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040300"
        }, 
        "source": "Pharmasset", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmasset", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2005"
    }, 
    "geocoordinates": {}
}